SVNS — Solvonis Therapeutics Share News
0.000.00%
Last trade - 00:00- £17.36m
- £15.72m
- 21
- 12
- 59
- 18
REG - Solvonis Therapeutic - US Patent allowance for PTSD discovery programme
AnnouncementREG - Solvonis Therapeutic - Research and Development Update – Q4 2025
AnnouncementREG - Solvonis Therapeutic - SVN-015 accepted into US NIDA funded programme
AnnouncementREG - Solvonis Therapeutic - Total Voting Rights
AnnouncementREG - Solvonis Therapeutic - Corporate Structure Update and Issue of Options
AnnouncementREG - Solvonis Therapeutic - Appoints global biopharma leader Paul Carter
AnnouncementREG - Solvonis Therapeutic - Raises £1.25 Million to Accelerate Programmes
AnnouncementREG - Solvonis Therapeutic - Half-year Report
AnnouncementREG - Solvonis Therapeutic - Solvonis secures exclusive CNS collaboration
AnnouncementRCS - Solvonis Therapeutic - Media Coverage: Small Cap Idea profile
AnnouncementREG - Solvonis Therapeutic - SVN-SDN-14 PTSD - Positive pre-clinical results
AnnouncementREG - Solvonis Therapeutic - Total Voting Rights
AnnouncementREG - Solvonis Therapeutic - Translational Bridging Studies
AnnouncementREG - Solvonis Therapeutic - Exercise of warrants
AnnouncementRCS - Solvonis Therapeutic - Solvonis Chair to speak at Lucid Capital Markets
AnnouncementREG - Solvonis Therapeutic - £1m subscription to accelerate AI drug discovery
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
AnnouncementREG - Solvonis Therapeutic - AGM Statement
AnnouncementREG - Solvonis Therapeutic - Holding(s) in Company
Announcement